- Prominent M&A TransactionAdvising
on its ~ $7.5 billion merger
with
2020 - Equity Capital MarketsActive Bookrunner
$14.4 Billion
Follow-on Offering
sale of ~22.4% stake in
2020 - Equity Capital MarketsActive Bookrunner
$3.5 Billion
Follow-on Offering &
5.0% Mandatory Convertible
Preferred2020 - Equity Capital MarketsJoint Bookrunner
$1.4 Billion
Initial Public Offering
2020 - Prominent M&A TransactionsAdvising
Advising DuPont on the merger of its Nutrition & Biosciences business with IFF via a Reverse Morris Trust
2019 - Prominent M&A TransactionAdvised
on its approximately $60 billion sale to
2019 - Special Committee & Board AssignmentsAdvised
The Independent Directors of the Board of
on its $40 billion combination with
2019 - RestructuringAdvising
on its pre-packaged chapter 11 restructuring of $9.3bn of debt and contingent liabilities and sales of the Lummus segment
Ongoing
- Cross Border TransactionAdvising
on its pending $6 billion take-private acquisition by
2019 - Equity Capital MarketsJoint Bookrunner
$717 million
Initial Public Offering2019 - Activism & Takeover DefenceAdvised
on its activism defense against
& on its $93 billion acquisition of
2019 - Cross Border TransactionsAdvised
on the $10 billion sale of its skin business to
2019 - RestructuringAdvising
on its chapter 11 restructuring of $2.8 billion of debt
Ongoing
- Activism & Takeover DefenseAdvised
on its activism defense against
2019 - Equity Capital MarketsJoint Bookrunner
$677 Million
Initial Public Offering
2019 - RestructuringAdvised
Ad Hoc Group of Unsecured Noteholders on Weatherford’s chapter 11 restructuring
2019 - Cross Border TransactionAdvised
on its $10 billion take-private acquisition of
2019 - Prominent M&A TransactionAdvised
on its ~$55 billion merger with
and simultaneous spin-offs of
2018